enGenes Biotech has developed customized solutions for the cost-effective production of recombinant proteins in microbial expression systems. The company’s unique enGenes-X-press Escherichia coli (E.coli) proprietary technology forms a production platform that achieves outstanding yields of soluble and active recombinant protein by reducing biological complexity. This is achieved by decoupling biomass growth from product formation.
R&D:enGenes Biotech offers patent-protected technology solutions and services for the microbial production of recombinant proteins that help pharma and enzyme manufacturer reduce cost of goods and that provide start-ups and small- and medium-sized enterprises (SMEs) access to difficult-to-express proteins vital for their research.
Production:enGenes expression products and services are highly relevant for companies with interest in developing cost-effective manufacturing processes for recombinant proteins. The world-leading X-press technology for growth-decoupled protein production allows enGenes to develop economic, scalable and efficient production processes within short time frames to enhance the commercial success of unique products.
Services:* Microbial cell line development * Expression vector design / engineering * Process development / scale-up & optimization * Proof-of-concept (POC) material production
Mooslackengasse 17
1190 Vienna
Vienna
Contact: Jürgen Mairhofer (CEO)
Telephone: +43 (1) 47654-6926
Email: office@engenes.cc
Website